MoonLake Immunotherapeutics (MLTX) Depreciation & Amortization (CF) (2021 - 2026)
MoonLake Immunotherapeutics' (MLTX) quarterly Depreciation & Amortization (CF) came in at $800000.0 in Q1 2026, up 111.64% year-on-year from $378000.0 in Q1 2025, and up 11.73% quarter-over-quarter from $716000.0 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 111.64% year-over-year to $800000.0 in Q1 2026; TTM through Mar 2026 was $3.0 million, a 109.52% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 86.86% from the prior year.
- Depreciation & Amortization (CF) grew to $800000.0 in Q1 2026 per MLTX's latest filing, from $716000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $800000.0 in Q3 2025 and bottomed at $2488.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $321000.0 (2024), against an average of $284795.1.
- Across the five-year window, Depreciation & Amortization (CF) sank 33.84% in 2022 and soared 11423.26% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $3289.0 in 2022, then changed by 0.0% to $3289.0 in 2023, then surged by 11423.26% to $379000.0 in 2024, then surged by 88.92% to $716000.0 in 2025, then gained by 11.73% to $800000.0 in 2026.
- Per Business Quant, the three latest MLTX Depreciation & Amortization (CF) figures stand at $800000.0 (Q1 2026), $716000.0 (Q4 2025), and $800000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | MoonLake Immunotherapeutics | 1.38 Bn | 1.02 Bn | - | 800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 716,000.00 |
| Dec 31, 2025 | 716,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 722,000.00 |
| Jun 30, 2025 | 722,000.00 |
| Mar 31, 2025 | 378,000.00 |
| Mar 31, 2025 | 378,000.00 |
| Dec 31, 2024 | 379,000.00 |
| Dec 31, 2024 | 379,000.00 |
| Sep 30, 2024 | 321,000.00 |
| Sep 30, 2024 | 321,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Dec 31, 2023 | 3,289.00 |
| Dec 31, 2023 | 3,289.00 |